The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• Complement activation significantly contributes to tissue injury in various glomerulonephritis types.
• Currently, no approved therapeutic agents effectively inhibit complement activation for human use.
• Soluble complement receptor 1 (sCR1) is a novel molecule designed to inhibit complement cascade activity.

Purpose of the Study:

• To evaluate the therapeutic efficacy of sCR1 in preclinical models of complement-mediated glomerulonephritis.
• To assess sCR1's impact on renal histology, proteinuria, and complement hemolytic activity.
• To determine sCR1's potential as a treatment for human immune glomerular diseases.

Main Methods:

• Rats were pretreated with sCR1 (60 mg/kg/day) during the induction of three complement-dependent glomerulonephritis models.
• Serum sCR1 levels and complement hemolytic activity were monitored.
• Renal histology, including glomerular C3 and fibrin deposits, and urine protein excretion were analyzed.

Main Results:

• sCR1 treatment maintained therapeutic serum levels (100-200 µg/mL) and reduced complement hemolytic activity to below 15%.
• Significant reductions in proteinuria, mesangiolysis, and inflammatory cell infiltration were observed in sCR1-treated groups across all models.
• Specifically, sCR1 ameliorated proteinuria in passive Heymann nephritis (199 ± 8.5 vs. 125 ± 16 mg/day, P < 0.002).

Conclusions:

• sCR1 demonstrates significant therapeutic potential by mitigating both structural and functional damage in experimental glomerulonephritis.
• The findings support further investigation of sCR1 as a viable treatment for human complement-mediated glomerular diseases.
• sCR1 effectively inhibits key components of the complement cascade, offering a targeted therapeutic approach.